Skip to main content

Table 1 Demographics, pulmonary function, and imaging measurements between subjects fully recovered and those with residual lung abnormalities

From: Altered immune surveillance of B and T cells in patients with persistent residual lung abnormalities 12 months after severe COVID-19

Variable

FRG n = 88

PLAG n = 21

p-value

Age, years (±SD)

54 ± 11

62 ± 9

0.002

Sex, male (%)

60 (68)

9 (43)

0.04

Values at hospital discharge time.

FVC % predicted (±SD)

93 ± 19

89 ± 26

0.5

DLCO % predicted (±SD)

82 ± 18

68 ± 18

0.001

Meters in 6MWT, (±SD)

438 ± 129

358 ± 150

0.02

% SpO2 at rest, (±SD)

94 ± 2

92 ± 3

0.01

% SpO2 post-exercise, (±SD)

90 ± 3

86 ± 5

< 0.001

Values at 1-year hospital discharge.

FVC % predicted (±SD)

91 ± 14

86 ± 15

0.3

DLCO % predicted (±SD)

85 ± 15

64 ± 10

< 0.001

Meters in 6MWT (±SD)

449 ± 126

330 ± 140

0.04

% SpO2 at rest (±SD)

93 ± 2

92 ± 3

0.3

% SpO2 post-exercise (±SD)

88 ± 4

83 ± 6

0.005

Basal CT Score (±SD)

20 ± 4

21 ± 4

0.2

CT Score 1 year (±SD)

4 ± 4

8 ± 5

< 0.001

  1. FRG: fully-recovery group; PLAG: persistent lung abnormalities group; SD: standard deviation, FVC: forced vital capacity, DLCO: single breath carbon monoxide diffusing capacity, 6MWT: 6-minute walk test, SpO2: peripheral oxygen saturation. CT: computed tomography